Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases - 24/04/13
Reprint requests: Magdalene A. Dohil, MD, 8010 Frost St, Suite 602, San Diego, CA 92123.Abstract |
In patients with psoriasis, there is an increased availability of drugs for treatment. However, there are important questions about drug safety for mothers with psoriasis and their fetuses. Currently, there are limited safety data for many of the medications used. In this article, we review current pregnancy risk information for medications commonly used in the treatment of psoriasis. In addition, a list of teratology information resources is included to help practicing clinicians find up-to-date information regarding the safety of the medications they prescribe.
Le texte complet de cet article est disponible en PDF.Abbreviations used : CsA, FDA, HPA, MTX, NSAID, OTIS, PUVA, RA, TERIS, TNF, UV
Plan
| Funding sources: None. |
|
| Disclosure: Dr Polifka is manager of the Teratogen Information System (TERIS) database. Drs Lam and Dohil have no conflicts of interest to declare. |
Vol 59 - N° 2
P. 295-315 - août 2008 Retour au numéro
Article précédent
- Epidermodysplasia verruciformis–associated and genital-mucosal high-risk human papillomavirus DNA are prevalent in nevus sebaceus of Jadassohn
- J. Andrew Carlson, Bernard Cribier, Gerard Nuovo, Angela Rohwedder
- Volunteers Needed
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?